---  
layout: startup_page  
title: "Third Arc Bio"  
id: "thirdarcbio.com"  
permalink: "/thirdarcbiothirdarcbio.com07232024/"  
website: "https://thirdarcbio.com/"  
funding_round: "Series A"  
funding_amount: "$165M"  
investors: "Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs Alternatives, BVF Partners LP, T. Rowe Price Associates, Inc., Janus Henderson Investors, abrdn Inc., Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures"  
about: "Third Arc Bio is a biotech company developing multifunctional antibodies optimized for T cell engagement in solid tumors and inflammatory & immunology (I&I) diseases. Their drug development engine leverages two technologies—a solid tumor synergy platform and an I&I platform—to create best-in-class T cell engagement for superior efficacy and safety. This approach aims to address significant unmet needs in oncology and autoimmunity."  
markets: "Biotechnology, Oncology, Immunology, Health Care, Life Science, Medical"  
hq: "Philadelphia, Pennsylvania, United States"  
founded_year: "2022"  
linkedin: "https://www.linkedin.com/company/third-arc-bio"  
twitter: ""  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/third-arc-bio"  
pitchbook: "https://pitchbook.com/profiles/company/615550-06"  

date_display: "23-Jul-2024"  
date: "2024-07-23"

# SEO Optimization  
meta_title: "Third Arc Bio - Series A Funding ($165M)"  
meta_description: "Third Arc Bio, Third Arc Bio is a biotech company developing multifunctional antibodies optimized for T cell engagement in solid tumors and inflammatory & immunology..."  
meta_keywords: "Third Arc Bio, Biotechnology, Oncology, Immunology, Health Care, Life Science, Medical, Series A funding"  
canonical_url: "https://startup.projectstartups.com/thirdarcbiothirdarcbio.com07232024/"  
---